Alert Indications, Safety, and Warnings

Serena CRT-Ps

Serena™ CRT-Ps are enabled with BlueSync™ technology, allowing for tablet-based programming and app-based remote monitoring. These devices include an exclusive algorithm to manage atrial fibrillation (AF).

Download Brochure
Image of Serena Quad CRT-P MRI SureScan and Serena CRT-P MRI SureScan
Alert Indications, Safety, and Warnings

Overview

The Future Is Here 

Meet Serena

Quad CRT-P MRI SureScan™

manage af
learn how
See more
Browse features

Unmatched feature suite

PhysioCurve Design for Patient Comfort

  • Tapered at the head and bottom of device to reduce skin pressure and promote patient comfort.
  • Designed with lead wrap in mind — landing area to minimize additional stresses on the lead.1
Side image of Serena Quad CRT-P MRI SureScan on white background

Exclusive algorithms to optimize CRT delivery

Improvement in CRT response  12%

Improvement in CRT patient response with AdaptivCRT™.*2

Reduction in  Hospitalizations 59%

Reduction in a patient’s odds of 30-day HF readmission with AdaptivCRT.3

Relative reduction in mortality  29%

AdaptivCRT is associated with a 29% relative reduction in mortality.†4

Exclusive algorithms to manage HF

46% reduction in AF risk with AdaptivCRT Algorithm‡5

Incidence of Primary End Point
(≥ 48 consecutive hours of AT/AF)

Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients

36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP™ Algorithm§6

Incidence of AT/AF Events Lasting 7 or More Days

Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients

Reimagined connectivity 

BlueSync Technology

BlueSync technology within Serena enables secure, wireless communication.

Learn about BlueSync
CareLink SmartSync interface shown on tablet

Tablet-based CareLink SmartSync™ device manager

Image of Serena Quad CRT-P MRI SureScan and Serena CRT-P MRI SureScan with Bluetooth icon

Serena CRT-Ps and
Serena Quad CRT-Ps

Image of app and home communicator on white background

MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator

Get Connected service shown on desktop monitor

CareLink network and the Get Connected service

STREAMLINED HEART FAILURE MANAGEMENT 

CareAlert Notifications

Time to a clinical decision was ~7x faster with the use of Medtronic CareAlert notifications compared to standard office follow-up.7

Clinical Management Alerts: 

  • AT/AF Daily Burden Enable
  • Avg. V. Rate during AT/AF
  • Monitored VT Episode
  • Ventricular Pacing < 90%

Device Management Alerts: 

  • Low Battery Voltage RRT
  • A. Pacing Enable
  • RV Pacing Enable
  • LV Pacing Enable
  • A. Capture Enable
  • RV Capture Enable
  • LV Capture Enable

System Features and Exclusive Algorithms

QUAD MODELS

BlueSync Technology 

AdaptivCRT Algorithm

Multiple Point Pacing

OptiVol™ 2.0 Fluid Status Monitoring

MRI SureScan™ Technology

PhysioCurve Design

Attain™ Performa™ Advanced Quadripolar Lead and VectorExpress™ LV Automated Test

NON-QUAD MODELS:

BlueSync Technology 

AdaptivCRT Algorithm

OptiVol 2.0 Fluid Status Monitoring

MRI SureScan Technology

PhysioCurve Design

Model Specifications

pdf Serena™ Quad CRT-P MRI SureScan™ Spec Sheet (.pdf)

W4TR02

4.5MB

pdf Serena™ CRT-P MRI SureScan™ Spec Sheet (.pdf)

W1TR02

4.2MB

Additional Resources 

Medtronic 24-hour Support

1-800-505-4636

Medtronic Academy

Find additional feature information along with a variety of educational resources and tools.

Visit Medtronic Academy
*

Comparing AdaptivCRT to Echo-optimized BiV pacing in patients with normal AV conduction, percentage of patients improved in Packer clinical composite score (CCS) at 6-month follow-up. CCS is a composite measure of mortality, HF hospitalizations, and symptomatic changes.

†

Patients who received AdaptivCRT were associated with a 29% relative reduction in all-cause mortality vs. conventional CRT (after adjusting for other potential risk factors including age, gender, LVEF, NYHA class, QRS duration, AF, CAD, hypertension, AV block, and LBBB).

‡

Most of the reduction in AF occurred in subgroups with prolonged AV conduction at baseline and with significant left atrial reverse remodeling.

§

Compared to matched control group.

References

1

Lulic T. March 26, 2013. Medtronic data on file.

2

Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm. September 2013;10(9):1368-1374.

3

Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail. July 2015;3(7):565-572.

4

Singh JP, et al. Improved Survival With Dynamic Optimization Of CRT Pacing Using AdaptivCRT Algorithm: Analysis Of Real-world Patient Data. Presented at HRS 2018 (Abstract B-AB37-06); Boston, MA.

5

Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. Heart Rhythm. December 2017;14(12):1820-1825.

6

Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. July 2019;42(7):970-979.

7

Crossley GH, Boyle A, Vitense H, Chang Y, Mead R, CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) Trial: The Value of Wireless Remote Monitoring With Automatic Clinician Alerts. J Am Coll Cardiol. March 2011;57(10):1181-1189.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.